Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/04/10/2860711/0/en/MaxCyte-to-Report-First-Quarter-2024-Financial-Results-on-May-7-2024.html
https://www.globenewswire.com/news-release/2024/04/02/2855927/0/en/MaxCyte-Signs-Strategic-Platform-License-with-Be-Biopharma-to-Support-the-Development-of-Engineered-B-Cell-Medicines-BCMs.html
https://www.globenewswire.com//news-release/2024/03/12/2845016/0/en/MaxCyte-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Reiterates-2024-Guidance.html
https://www.globenewswire.com//news-release/2024/03/04/2839956/0/en/MaxCyte-Initiates-Full-Year-2024-Guidance-and-Reaffirms-2023-Preliminary-Results.html
https://www.globenewswire.com//news-release/2024/02/09/2826790/0/en/MaxCyte-to-Report-Fourth-Quarter-and-Full-Year-2023-Financial-Results-on-March-12-2024-and-Participate-in-Upcoming-Investor-Conferences.html
https://www.globenewswire.com/news-release/2024/01/30/2819968/0/en/MaxCyte-and-Wugen-Sign-Strategic-Platform-License-to-Expedite-Scale-Up-of-Clinical-and-Commercial-Manufacturing-of-Wugen-s-Investigational-Allogeneic-Off-the-Shelf-Cell-Therapies-f.html
https://www.globenewswire.com//news-release/2024/01/23/2814060/0/en/MaxCyte-Signs-Strategic-Platform-License-with-Imugene-to-Advance-their-Cancer-Immunotherapy-Programs.html
https://www.globenewswire.com//news-release/2024/01/08/2805846/0/en/MaxCyte-Announces-Preliminary-Unaudited-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html
https://www.globenewswire.com//news-release/2024/01/03/2803278/0/en/MaxCyte-and-Lion-TCR-form-Partnership-to-Support-Global-Expansion-of-Lion-TCR-s-TCR-T-Cell-Pipeline.html
https://www.globenewswire.com//news-release/2024/01/02/2802418/0/en/MaxCyte-Confirms-Appointment-of-Maher-Masoud-as-President-Chief-Executive-Officer-and-Director.html